Abstract: The present invention relates to a method for oligomerizing olefins, including the steps of: carrying out an oligomerization reaction of olefins by injecting an oligomerization transition metal catalyst, a cocatalyst, an olefin monomer and a solvent into a reactor; and injecting, into the reaction product of the oligomerization reaction, a catalyst inactivator including a gaseous inorganic material that contains oxygen.

Abstract: Disclosed is a process for the alkylation of an aliphatic organic compound comprising: (a) providing a catalyst comprising one or more zeolitic materials having a BEA framework structure, wherein the BEA framework structure comprises YO2 and optionally comprises X2O3, wherein Y is a tetravalent element, and X is a trivalent element, (b) contacting the catalyst with one or more aliphatic organic compounds in the presence of one or more alkylating agents in one or more reactors for obtaining one or more alkylated organic compounds, wherein the one or more zeolitic materials are obtainable from a synthetic process which does not employ an organotemplate as structure directing agent.

Abstract: An invention is provided for conversion of methane into hydrocarbon fuels is disclosed. The invention includes providing methane to an illumination chamber, and illuminating the methane with substantially narrow bandwidth photons of a predefined wavelength. The photons are provided from a substantially uncollimated light source producing photon intensities less than 10 Watt/m2. As a result, the methane is placed in an excited state that results in the molecules of the methane reacting more readily with other molecules to form a final product.

Abstract: This disclosure provides improved processes for converting aromatic hydrocarbons, such as benzene/toluene, alkylation, transalkylation, or isomerization. In an embodiment, a process comprises utilizing a passivated reactor to reduce deactivation of a molecular sieve catalyst. Additional measures such as the use of an auxiliary catalyst and/or an elevated reactor pressure may be used to further reduce deactivation of the molecular sieve catalyst.

Abstract: A process for producing olefins by cracking paraffins in the presence of methane. In the conventional steam cracking processes for olefin production, steam is used as a diluent in the feed mixture to the thermal cracker. In the processes provided herein, methane replaces steam as a diluent in the feed mixture to the thermal cracker. Replacing steam with methane as a diluent has a potential for cost savings in the construction and operation of a thermal cracking plant for olefin production. In addition, it leads to a much simpler cracking process compared to the conventional steam cracking technology as in the state of the art.

Abstract: A process for making p-xylene comprising co-feeding toluene with C8 aromatics into a vapor phase isomerization unit can improve xylenes loss and benzene selectivity in ethylbenzene conversion

Abstract: Processes and systems for upgrading natural gas liquids. At least a portion of the natural gas liquid components in a shale gas stream can be dehydrogenated to their corresponding olefin derivatives prior to separating any methane from the liquids. Further processing subsequent to dehydrogenation could include various separations, oligomerizing olefins produced in the dehydrogenation step, recovering desired products, etc. The order of the processing steps subsequent to dehydrogenation could be adjusted in various cases.

Abstract: This application is directed to use of transition metal-ligand complexes to hydrogenate fluorinated esters and carboxamides into fluorinated hemiacetals. Methods for synthesis of certain ligands are also provided.

Abstract: The present invention relates to the manufacturing of a process of alkyl 2-acetyl-5,9,13-trimethyltetradeca-4,8,12-trienoates and alkyl 2-acetyl-9,13-di-methyl-5-methylenetetradeca-8,12-dienoate as well as 6,10,14-trimethylpenta-deca-5,9,13-trien-2-one and 10,14-dimethyl-6-methylenepentadeca-9,13-dien-2-5 one and 6,10,14-trimethylpentadecan-2-one.

Abstract: A process for making a high purity salt comprises the steps of providing an organic compound, providing a metal salt, adding the metal salt and organic compound to an aqueous medium, heating the reaction mixture to react the organic compound and the metal salt to form an organic salt, collecting the organic salt, exposing the collected organic salt to microwave radiation, and exposing the collected organic salt to infrared radiation.

Abstract: Processes for separating a di-carboxylic acid or salt thereof from a mixture containing the di-carboxylic acid or salt thereof and one or more other components are provided. Also separation media useful for these separation processes is provided. In particular, processes for preparing an aldaric acid are described, such as glucaric acid from glucose, which includes separating the aldaric acid from the reaction product. Also, various glucaric acid products are described.

Abstract: A method of preparing ?-hydroxycarboxylic acid ester comprises mixing an alkylene oxide, a monohydric alcohol and a composite catalyst, and performing a carbonylation esterification reaction in a carbon monoxide atmosphere to obtain the ?-hydroxycarboxylic acid ester. The composite catalyst comprises a main catalyst, a cocatalyst and a reducing agent. the main catalyst is at least one of a cobalt salt, cobalt oxide and cobalt hydroxide. The cocatalyst is a nitrogen-containing heterocyclic compound. The reducing agent is a base metal. The method is an atomic reaction type process, does not produce three wastes, and has high conversion rate. It is a green environmental protection process. The composite catalyst used does not contain Co2(CO)8. The raw materials and catalyst used are all cheap and easily available. The composite catalyst can be used repeatedly at a lower cost, and is suitable for industrial applications.

Abstract: The present invention relates to a method for preparing acetate compounds using ketene.

Abstract: Disclosed are a compound represented by formula (I), a resin including a structural unit derived from the compound, and a resist composition: wherein R1 represents an alkyl group which may have a halogen atom, a hydrogen atom or a halogen atom; A1 represents a single bond or *-A2-CO—O—; A2 and A3 represent an alkanediyl group; W represents a divalent monocyclic saturated alicyclic hydrocarbon group; R2 and R3 each represent a hydrogen atom or a hydrocarbon group which may have a fluorine atom, etc., R4 represents a hydrogen atom, —CH2— in the group may be replaced by —O—, —S—, etc., R2 and R3, or R2, R3 and R4 may be bonded each other to form a ring which may have a fluorine atom or an alkyl group.

Abstract: Activated fatty acids, pharmaceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty acids are provided herein.

Abstract: The present invention relates to a process for purifying a mixture comprising MEG, MEA, EDA and DETA, and low boilers having a boiling point not higher than PIP and high boilers having a boiling point not lower than AEEA, wherein the process comprises the following steps: a) separating a mixture comprising MEG, MEA, EDA and DETA, and low boilers having a boiling point not higher than PIP and high boilers having a boiling point not lower than AEEA, into (i) a mixture A comprising EDA and the low boilers having a boiling point not higher than PIP; and (ii) a mixture B comprising MEA; and (iii) a mixture C comprising MEG, DETA and the high boilers having a boiling point not lower than AEEA; b) separating mixture C from stage a) into (i) a mixture D comprising MEG; and (ii) a mixture E comprising MEG, DETA and the high boilers having a boiling point not lower than AEEA; c) separating mixture E from stage b) either into (i) a mixture F comprising MEG and DETA; and (ii) a mixture G comprising the high boi

Abstract: The present invention relates to a process for removing NMEDA from a mixture comprising water (H2O), ethylenediamine (EDA) and N-methylethylenediamine (NMEDA) by a rectification in a rectification column (NMEDA removal), wherein the rectification is conducted at a bottom temperature TB of 155° C. or less and the mixture comprises at least the amount of water as required for the formation of a high-boiling azeotrope of EDA and water at the corresponding bottom temperature.

Abstract: A compound represented by specific chemical formula, a core including the same, and core-shell dye including a shell surrounding the core, a photosensitive resin composition including the same, and a color filter manufactured using the photosensitive resin composition are disclosed.

Abstract: The present invention relates to lyso-diacylglyceryltrimethylhomoserine (lyso-DGTS) or derivatives thereof for use in the treatment of atherosclerotic cardiovascular disease, and further provides particular such lyso-DGTS derivatives.

Abstract: A method for producing a homocyclic or heterocyclic compound includes reacting a compound of formula (I) with a compound of formula (II) in presence of a base: In formula (I), B is an unsaturated moiety selected from substituted or unsubstituted vinylene, ethynylene, aryleneethynylene, substituted or unsubstituted arylenevinylene, and a combination thereof, the vinylene or arylenevinylene has n (=0, 1 or 2) substituent(s) R2, G is an electron-withdrawing group, R1 is hydrogen or a substituent, and two of R1, R2 and G may joint together to form a ring. In formula (II), R3 and R4 are independently hydrogen or a substituent, R5 is an electron-withdrawing group, and two of R3, R4 and R5 may joint together to form a ring. The conjugate acid of the base has a pKa in the range of 1 to 15.

Abstract: Novel compounds usable in modulating an activity or function of a voltage-dependent potassium channel and/or of TRPV1 are provided. The compounds are represented by Formula I as described and defined in the specification.

Abstract: Crystals of (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N?,2-dimethylmalonamide having diffraction peaks at diffraction angles (2?) of 3.8±0.2°, 7.7±0.2°, and 10.8±0.2°, etc., or 8.2±0.2°, 12.4±0.2°, and 13.3±0.2°, etc., in powder X-ray diffraction, a production method thereof, and a pharmaceutical composition.

Abstract: The present disclosure relates to an ?-aminoamide derivative compound and a pharmaceutical composition containing the same. According to various embodiments of the present disclosure, provided is a therapeutic agent which can overcome the disadvantages of existing drugs used as a MAO-B inhibitor and, specifically, reversibly inhibits MAO-B through a non-covalent bond so as to alleviate or eliminate the side effects of the existing drugs which exhibit a therapeutic effect by irreversibly acting via a covalent bond with MAO-B. Particularly, a new compound having superior stability and efficacy compared to the existing reversible MAO-B inhibitors may be provided.

Abstract: A novel method for production of hydroxamic acid derivative using a compound represented by the formula [12] as an intermediate, and intermediate therefor. wherein R1 represents a methyl group or the like; R2 represents a methyl group or the like; and R5 represents a hydrogen atom or the like.

Abstract: The present invention relates to a urea and urethane group containing product comprising one or more species of formula (I) R1—O—(C?O)—NH—R2—NH—(C?O)—NH—R3—NH—[—(C?O)—NH—R4—NH—(C?O)—NH—R3—NH—]n—(C?O)—NH—R2—NH—(C?O)—O—R1 (I), wherein R1 independently represents a non-aromatic hydrocarbyl group having 14 to 30 carbon atoms; R2 independently represents alkyl-substituted aromatic hydrocarbyl groups having 7 to 12 carbon atoms; R3 independently represents hydrocarbyl groups having 2 to 36 carbon atoms, which can be interrupted by 1 to 17 ether oxygen atoms in case of aliphatic hydrocarbyl groups; R4 independently represents hydrocarbyl groups having 2 to 36 carbon atoms; n is an integer from 0 to 200; and wherein on average from 40 mol-% to 100 mol-% of all R3 and R4 groups contained in the one or more species of formula (I) are acyclic aliphatic hydrocarbyl groups which, in case of R3, can be interrupted by 1 to 17 ether oxygen atoms.

Abstract: Electrolytes and polymers for a lithium battery can include a fluorinated aryl sulfonimide salt or fluorinated aryl sulfonimide polymer.

Abstract: A method of distilling a liquid containing dimethyl sulfoxide using a distillation system, including mixing sodium carbonate with a liquid containing dimethyl sulfoxide at a bottom of the distillation system such that sodium carbonate accounts for 0.005% to 25% by weight relative to 100% by weight of the liquid containing dimethyl sulfoxide and sodium carbonate in total at the bottom of the distillation system and heating the bottom; and obtaining a distillate containing dimethyl sulfoxide at a position lower than a position at which the liquid containing dimethyl sulfoxide is introduced and higher than a position of the heating portion.

Abstract: The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as defined in the specification.

Abstract: The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.

Abstract: The present invention provides a cationic lipid which is able to be used for nucleic acid delivery to the cytoplasm. A cationic lipid according to the present invention is, for example, a compound represented by formula (1) or a pharmaceutically acceptable salt thereof, wherein L1 and L2 independently represent an alkylene group having 3 to 10 carbon atoms; R1 and R2 independently represent an alkyl group having 4 to 24 carbon atoms or an alkenyl group having 4 to 24 carbon atoms; R3 represents an alkyl group having 1 to 3 carbon atoms; and X1 represents a single bond or CO—O—.

Abstract: A method for producing a maleimide compound having a group represented by the formula (a1), the method including condensing a primary amino group in a raw material compound having the primary amino group and dicarboxylic anhydride represented by the formula (a2) to generate a group represented by the formula (a3); and heating a compound having the group represented by the formula (a3), and converting the group represented by the formula (a3) into the group represented by the formula (a1).

Abstract: This invention relates to crystalline forms of (R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile, a modulator of the androgen receptor, and methods for the use in treatment.

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.

Abstract: The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.

Abstract: The invention relates to a compound chosen from the compounds of formula (I) below, the optical and geometrical isomers thereof and the tautomers thereof, and also the addition salts thereof with an acid or a base, and the solvates thereof: (I). The invention also relates to the use of these particular compounds and the compositions for dyeing keratin fibers.

Abstract: Disclosed are crystalline salts of Compound I, methods of preparing them, and related pharmaceutical preparations thereof. Also disclosed are methods of treatment using the crystalline salts of the invention.

Abstract: The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.

Abstract: The invention relates to a salt of 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone), wherein the salt is 3-methyl-1-phenyl-2-pyrazolin-5-one napadisylate or 3-methyl-1-phenyl-2-pyrazolin-5-one hemi-napadisylate. These napadisylate salts of edaravone are easy to manufacture and dissolve more rapidly in water than the free edaravone base. In addition, the edaravone salts of the present invention are very stable and easy to handle. The invention also relates to a pharmaceutical composition comprising the aforementioned edaravone salt and to a method of preparing such edaravone salt.

Abstract: The present disclosure relates to an adhesive resin composition for bonding semiconductors, including: a thermoplastic resin; a thermosetting resin; a curing agent; and a compound having a specific structure, and an adhesive film for semiconductors including the same.

Abstract: The present invention relates to sulfonamide compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present sulfonamide compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing sulfonamide compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.

Abstract: The present invention relates to methods for producing particles of metaxalone using dry milling processes as well as compositions comprising metaxalone, medicaments produced using metaxalone in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of metaxalone administered by way of said medicaments.

Abstract: A catalyst composition comprising at least a catalyst compound selected from multi metal cyanide compounds for the selective production of oxazolidinone compounds by reacting an isocyanate compound with an epoxide compound and oxazolidinone comprising materials obtained using said catalyst compound.

Abstract: This invention relates to a process for the epoxidation of a tetrasubstituted alkene such as terpinolene to the corresponding epoxide such as terpinolene epoxide by reacting the tetrasubstituted alkene with performic acid prepared in situ from formic acid and hydrogen peroxide in the presence of at least one buffering agent. Further, the invention relates to the use of an oxidizing agent comprising hydrogen peroxide and formic acid for the in-situ epoxidation of a tetrasubstituted alkene.

Abstract: To provide a method that can efficiently produce 2,5-bis(aminomethyl)tetrahydrofuran. The method for producing 2,5-bis(aminomethyl)tetrahydrofuran, the method including subjecting 2,5-bis(aminomethyl)furan to a reaction with hydrogen source by using a hydrogenation catalyst to obtain 2,5-bis(aminomethyl)tetrahydrofuran.

Abstract: The present disclosure provides a process for producing an aliphatic sulfonyl azide anhydride and the resultant aliphatic sulfonyl azide anhydride composition. The process includes: (i) thio-acetoxylating an alkenyl carboxylic acid anhydride to form a thioacetate anhydride intermediate, (ii) oxy chlorinating the thioacetate anhydride intermediate to form a sulfonyl chlorideanhydride N intermediate; and (iii) azidizing the sulfonyl chloride anhydride intermediate to form an aliphatic sulfonyl azide anhydride.

Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.

Abstract: The present application relates to a specific fluorene derivative, to its use in an electronic device and to an electronic device comprising said fluorene derivatives. Further, the present application relates to a process for the preparation of such fluorene compounds and to oligomers, polymers or dendrimers as well as formulations or compositions comprising one or more of said fluorene compounds.

Abstract: Methods for producing ferric maltol compositions, such as ferric trimaltol, from elemental iron, and ferric maltol compositions produced by these methods and their uses are described.

Abstract: The invention relates to a method for directly producing morin derivatives and high-purity morin of formula (I). The invention also relates to morin derivatives and high-purity morin that can be obtained using the claimed method.